INTRODUCTION
Apoptosis occurs through a series of controlled events that ensure cellular remnants are contained and eliminated without initiating an inflammatory immune response (Grimsley and Ravichandran, 2003; Henson et al., 2001; Savill and Fadok, 2000) . In general, apoptotic cell sensing systems recognize lipid or carbohydrate changes displayed on the outside of the dying cell, such as phosphatidylserine (PtdSer), a membrane lipid normally restricted to the inner leaflet of the plasma membrane (Green, 2003; Ravichandran and Lorenz, 2007) . The loss of membrane asymmetry during apoptosis also leads to oxidation of phospholipids. These ''eat-me'' signals are bound by bridging molecules including milk fat globule EGF factor 8 (MFGE8), growth-arrestspecific 6 (GAS6), and complement factor C1q on the surface of apoptotic cells (Botto et al., 1998; Hanayama et al., 2002; Ishimoto et al., 2000) . Bridging molecules facilitate phagocytosis through interaction with specific receptors expressed on macrophages and dendritic cells, including the TAM family of receptors (Tyro3, Axl, and Mer), a v b 3 -integrin, Tim4, and CD36 (Fadok et al., 1998a; Lemke and Rothlin, 2008; Miyanishi et al., 2007; Ravichandran and Lorenz, 2007) .
After apoptotic cell engulfment, macrophages activate tolerogenic pathways in an effort to prevent immune responses against self-antigens ( Henson and Hume, 2006; Taylor et al., 2005) . Tolerance is accomplished through several distinct mechanisms, including suppression of inflammatory cytokine production and release of anti-inflammatory cytokines such as IL-10 and TGF-b (Fadok et al., 1998b; Li and Flavell, 2008; Voll et al., 1997) . If phagocytosis or tolerogenic pathways are impaired, chronic accumulation of free apoptotic material can have pathological consequences (Henson and Hume, 2006; O'Shea et al., 2002) . The resulting inflammation and stimulation of adaptive immune responses against self-antigens may ultimately trigger autoimmunity (Ravichandran and Lorenz, 2007; Savill et al., 2002) . Interestingly, TAM receptors have recently been linked to the suppression of TLR signaling, revealing one mechanism by which apoptotic cell clearance and immune tolerance are coupled (Lemke and Rothlin, 2008; Rothlin et al., 2007) . Transcriptional pathways integrating apoptotic cell clearance and the immunosuppressive effects of apoptotic cells remain to be characterized.
Liver X receptors (LXRa and LXRb) are oxysterol-activated transcription factors that sense elevated cellular cholesterol (Peet et al., 1998; Repa and Mangelsdorf, 2002) . Accumulation of excess lipoprotein-derived cholesterol in macrophages activates LXR and triggers the induction of a transcriptional program for cholesterol efflux (Castrillo and Tontonoz, 2004) . Pharmacologically activated LXRs have also been shown to transrepress inflammatory gene expression (Castrillo et al., 2003a; Ghisletti et al., 2007; Joseph et al., 2003) . However, the physiological relevance of endogenous transrepression pathways has remained unclear, because no biological processes have been definitively shown to be dependent on both activation and transrepression. We reasoned that the dual abilities of LXRs to respond to phagocytosed lipids and to modulate inflammation places them in an ideal position to tailor macrophage responses to particular phagocytic contexts. We found that the LXR pathway was essential for efficient apoptotic cell clearance through positive induction of Mer, as well as for the maintenance of immune tolerance through transrepression of inflammation in response to phagocytosis. These results implicate LXRs in a positive transcriptional feedback loop that couples apoptotic cell clearance with the suppression of autoimmunity.
RESULTS

Defective Phagocytosis of Apoptotic Cells in LXR-Deficient Macrophages
Previous work has established that LXRa and LXRb (encoded by the genes Nhr1h3 and Nhr1h2) are important for the macrophage response to lipoprotein uptake (Castrillo and Tontonoz, 2004) , but their impact on other phagocytic processes is unknown. To investigate a possible role of LXRs in apoptotic cell clearance, thioglycollate-elicited macrophages obtained from wild-type (WT) and LXR-deficient mice lacking both LXRa and LXRb proteins (LXR DKO) mice were cocultured in vitro with apoptotic thymocytes (ATs). Engulfed ATs were differentiated from associated ATs through use of a cell dissociation buffer (Krysko et al., 2006) and by scoring engulfed cells by confocal microscopy ( Figures 1A and 1B) . We found that ATs were efficiently engulfed by WT macrophages, whereas phagocytosis by LXR-deficient macrophages was markedly reduced. By contrast, phagocytosis of GFP-E. coli or fluorescent microspheres was comparable in WT and LXR DKO macrophages, indicating that loss of LXR function does not lead to a general defect in phagocytosis ( Figure S1 available online). To determine whether apoptotic cell clearance could be improved by exogenous stimulation of LXR activity, macrophages were cultured with the synthetic LXR agonist GW3965 (Collins et al., 2002) for 48 hr and then challenged with apoptotic cells for 1 hr. GW3965 enhanced WT macrophage phagocytosis but had no effect in macrophages lacking LXRs ( Figures 1C and 1D ).
These LXR-dependent mechanisms appear to function in vivo, too. Resident macrophages of LXR-deficient mice exhibited reduced AT association (combination of bound and engulfed cells) in response to intraperitoneal injection of CFSE-labeled ATs compared to macrophages of C57BL/6 mice ( Figure 1E ). Furthermore, primary macrophages from mice treated with GW3965 for 3 days displayed increased AT association compared to vehicle-treated mice ( Figure S2 ). AT association in this assay was specific for macrophages, as indicated by the fact that we observed no association of ATs with peritoneal B cells ( Figure S3A ). Furthermore, defective AT association of LXR DKO macrophages could not be attributed to loss of regulation of the established LXR targets Abca1, Abcg1, or Apoe, because mice lacking expression of these genes showed comparable AT association to WT cells ( Figures S3B and S3C) . Note, Abca1 null mice on a C57Bl/6 background are not viable and therefore comparison was made to background-matched Abca1 +/+ controls ( Figure S4C ). LXR-dependent regulation of AT phagocytosis was also observed in both immature and mature dendritic cells ( Figure S3D ). Thus, loss of LXR functions alters the phagocytic capacity of both macrophages and dendritic cells.
Altered Macrophage Functions in LXR-Deficient Lymphoid Tissues
Next we investigated the potential consequences of loss of LXR function for apoptotic cell clearance in vivo. Immunofluorescence analysis of LXR DKO spleens showed increased numbers of germinal centers staining with peanut agglutinin (PNA) and increased numbers of immunoglobulin G (IgG)-producing cells ( Figure 2A ). In addition, LXR DKO spleens showed an anomalous distribution of CD68 + ''tingible body'' macrophages (Rabinowitz and Gordon, 1991) . Staining of endothelial sinus-lining cells with MadCAM-1 also demonstrated defects in the organization of the spleen in older LXR-deficient mice ( Figure 2A ). Macrophages present in germinal centers participate in the clearance of apoptotic B cells (Smith et al., 1991; Taylor et al., 2005) . Accordingly, few apoptotic cells were typically observed in the spleens of WT mice, and these colocalized with macrophages ( Figure 2B , left). In contrast, despite comparable numbers of splenic CD68 + macrophages (data not shown), many free apoptotic bodies were present in LXR DKO spleens, consistent with inefficient macrophage engulfment ( Figure 2B , right). Free apoptotic bodies were also observed in several other tissues of LXR DKO mice, including thymus, lung, and testis ( Figure S4A ). We have previously reported that macrophages lacking LXR expression undergo apoptosis when challenged with Listeria monocytogenes (Joseph et al., 2004) . However, LXR DKO macrophages did not undergo apoptosis at an increased rate compared to WT when challenged with ATs. The apoptotic bodies observed in LXR DKO spleens colocalized with B cells ( Figure S4B ) but not with macrophages ( Figure 2B ). Furthermore, LXR DKO macrophages challenged with ATs in vitro for extended times (18 hr) did not undergo apoptosis as assayed by TUNEL staining ( Figures S4C and S4D and data not shown).
We also evaluated the clearance of dying thymocytes after dexamethasone (dex)-induced apoptosis in vivo. Both WT and LXR DKO thymocytes showed comparable sensitivity to dexor UV irradiation-induced apoptosis in vitro ( Figure S5 ). After 24 hr of dex stimulation, thymi of WT mice showed a marked loss of mass and few Annexin V + cells, consistent with effective clearance of apoptotic cells ( Figure 2C ). By contrast, despite similar recruitment of CD68 + macrophages, LXR DKO thymi contained increased numbers of free Annexin V + cells and mass was not altered. In agreement with these results, transmission electron microscopy analysis of thymic sections revealed effective engulfment of apoptotic bodies by WT macrophages ( Figure 2D ; see inset, a macrophage with five apoptotic cells inside), whereas abundant clusters of free apoptotic cells (large dark staining bodies) were observed in LXR DKO mice. Thus, loss of LXR function results in defective clearance of apoptotic cells in vivo.
Transcriptional Regulation of Genes Involved in Clearance of Apoptotic Cells by LXRs
To identify LXR target genes involved in the removal of apoptotic cells, we conducted transcriptional profiling studies by using RAW264.7 cells ectopically expressing LXRa (Venkateswaran et al., 2000) (RAW-LXRa; Figure S6A ). These studies identified the gene encoding the Mer receptor tyrosine kinase (Mertk) (Camenisch et al., 1999; Graham et al., 1995) as an LXR-responsive gene ( Figure S6B ). Mer plays an important role in the clearance of dying cells through interaction with PtdSer-bound Gas6 on the surface of apoptotic cells (Cohen et al., 2002; Lemke and Rothlin, 2008; Scott et al., 2001) . Real-time PCR and immunoblot analysis of RAW-LXRa cells and primary macrophages confirmed that Mertk was a bona fide LXR-responsive gene ( Figures 3A-3C ). Expression of Mertk was induced by LXR and RXR agonists in WT, LXRa-deficient, and LXRb-deficient but not in LXR DKO primary macrophages ( Figure 3B ; Figure S6B ), indicating that Mertk responds to both LXRa and LXRb. Expression of the other members of the TAM family, Tyro3 and Axl, was not altered by LXR agonists ( Figure S6A and data not shown). Although several different RXR heterodimeric nuclear receptors are expressed in macrophages, the effect of RXR agonists on Mer expression was absolutely dependent on LXR expression (Figures 3B and 3C) .
Importantly, Mer expression was also responsive to LXR activation in vivo. Treatment for 3 days with GW3965 induced expression of Mer in spleen and lung of WT but not LXR DKO mice ( Figure 3D ). Basal expression of Mertk mRNA was also impaired in primary cells and lymphoid organs of LXR DKO mice ( Figures 3C and 3D and not shown). To determine whether the Mertk gene was a direct target for LXRs, we analyzed the 5 0 -promoter region. A potential LXRE (LXR response element) was identified 1.7 kb upstream of the transcription start site ( Figure S7A ). Electromobility shift assays demonstrated that in vitro translated LXR and RXR proteins bound as heterodimers to a radiolabeled oligonucleotide containing this element (Figure S7A) . Binding of LXR to the Mertk promoter was also confirmed by chromatin immunoprecipitation (ChIP) analysis of RAW-FLAG-LXRa cells ( Figure S7B ). ChIP assays with either FLAG or RXRa antibodies demonstrated the presence of LXR/ RXR heterodimers on the Mertk promoter. Furthermore, GW3965 caused release of N-CoR from and recruitment of RNA polymerase II to both the Mertk and Srebp-1c promoters in RAWLXRa cells ( Figure S7C ).
Ingestion and degradation of apoptotic cells by macrophages leads to the accumulation of cellular components, including cholesterol. We hypothesized that such accumulation might activate LXR signaling. Remarkably, expression of Mertk and a battery of known LXR targets (Abca1, Abcg5, Pltp, and Scl2a4), was induced by apoptotic thymocytes in WT macrophages ( Figure 3A ). By contrast, induction of these genes by ATs was severely impaired LXR DKO macrophages. Some residual induction of Mertk by ATs remained in LXR DKO macrophages, pointing to the contribution of an additional, LXR-independent pathway. Genes not regulated by LXR, such as Cd36, were induced by ATs to comparable degrees in both WT and LXR DKO macrophages ( Figure 3A ). Expression of Mfge8 was not responsive to AT or LXR signaling. Thus, LXR mediates the AT-dependent regulation of a specific subset of genes involved in phagocytosis and lipid metabolism. These results suggest that engulfment of apoptotic cells leads to activation of LXRs and the promotion of Mer expression, providing positive feedback to facilitate further apoptotic cell uptake. In support of this idea, we found that macrophages challenged with one round of ATs show increased phagocytic capacity when challenged with a second round, and that this response was dependent on LXR expression ( Figure 3E ). Furthermore, depletion of sterols from ATs by means of methyl beta-cyclodextran treatment reduced their ability to induce LXR target gene expression (Mertk, Abca1) after ingestion by macrophages, but not their ability to induce Marco or Cd36 expression. These results strongly suggest that cholesterol and/or oxysterol species present in ATs can serve as LXR agonists ( Figure 3F ). In support of this idea, Lauber et al. (2003) Mer and LXR have previously been implicated in the repression of macrophage inflammatory signaling (Camenisch et al., 1999; Joseph et al., 2003; Rothlin et al., 2007) . Based on the abnormal phagocytic response of LXRdeficient mice to apoptotic cells, we predicted that regulation of inflammatory pathways during the engulfment process might be also altered in LXR DKO macrophages. We therefore tested the ability of apoptotic cells to engage anti-inflammatory mechanisms in the presence or absence of LXR. In agreement with previous studies (Fadok et al., 1998b; Voll et al., 1997) , ATs promoted the expression of immunosuppressive mediators such as TGF-b and IL-10 in WT macrophages (Figures 4A and 4B) . However, induction of these genes was impaired in macrophages lacking LXRs. Furthermore, inadequate engulfment of apoptotic cells by LXR-deficient macrophages led to the inappropriate expression of proinflammatory mediators, such as IL-1b and MCP-1, and enhanced induction of Marco (Figures 4A and 4B) . LXR agonist alone repressed basal expression of the genes encoding IL-1b and MCP-1, but did not induce expression of those encoding TGF-b or IL-10 ( Figure S8A and data not shown).
We also tested the ability of apoptotic cells to counteract inflammatory signaling induced by ligands for toll-like receptors (TLR) 2, 3, and 4 ( Figure 4C ; Figure S8B ). Culturing primary WT macrophages with ATs inhibited the stimulus-dependent induction of genes encoding IL-12p40 and IL-1b, in agreement with previous work (Fadok et al., 1998b; Voll et al., 1997) . By contrast, incubation of apoptotic thymocytes with LXR-deficient macrophages resulted only in partial repression of inflammatory gene expression induced by LPS and other TLR activators (Figure 4C ; Figure S8B ). Thus, LXR signaling couples the engulfment of apoptotic cells to the suppression of inflammatory pathways.
LXR-Dependent Expression of Mer Promotes Apoptotic Cell Clearance in Macrophages
To further evaluate the role of Mer in LXR-dependent responses to apoptotic cells, we performed gain-of-function experiments. Retroviral expression of LXRa in RAW264.7 cells promoted the engulfment of ATs in response to GW3965 (Figures 5A and 5B ). Ectopic expression of Mer itself also enhanced the phagocytosis of apoptotic cells, but this effect was not markedly modified by the addition of GW3965 (Figures 5A and 5B) . Treatment of WT macrophages with a Mer-blocking antibody (Sen et al., 2007) decreased AT phagocytosis to a similar degree to that observed in LXR-deficient macrophages ( Figure 5C ). To provide direct evidence for a link between LXR activation, Mer, and phagocytosis, we performed knockdown studies. RAW-LXRa cells were transfected with nonspecific or several different Merspecific siRNAs ( Figure 5D ) and assayed for phagocytic activity. Reduction of Mer expression inhibited phagocytosis induced by LXR ligand, whereas nonspecific siRNA had no effect in both primary mouse macrophages and RAW cells (Figures 5E and  5F ). To further confirm the role of the LXR-Mer pathway, we performed additional knockdown studies in primary macrophages. Protein knockdown was verified by immunoblotting ( Figure 5G ). Reduction in Mer expression effectively inhibited the effect of LXR agonist on AT uptake, whereas knockdown of ABCA1 and apoE did not ( Figure 5H ). These data show that LXR signaling promotes the clearance of apoptotic cells, at least in part, through induction of Mer expression. Figure S11 ). Furthermore, lymphoproliferative disease in LXR DKO mice did not appear to be a consequence of the loss of CD4
LXR-Deficient
+ regulatory T cells ( Figure S11 ). Defects in Mer signaling have previously been reported to result in the loss of self-tolerance and lupus-like disease (Cohen et al., 2002; Scott et al., 2001) . Accordingly, elevated quantities of antibodies to nuclear proteins (ANA, antinuclear antibodies), double-stranded DNA (dsDNA), and histones were detected in the serum of LXR DKO mice ( Figure 6C) . A major pathogenic consequence of autoantibody production is the deposition of immune complexes in the kidney, leading to glomerulonephritis. Examination of kidney sections from WT and LXR-deficient mice revealed conserved renal architecture in both genotypes ( Figure 6D and data not shown). However, LXR DKO mice exhibited glomerular enlargement, mesangial proliferation, and glomerular basement membrane thickening ( Figure 6D ). Immunofluorescence microscopy revealed marked age-dependent glomerular deposition of IgG-containing immune complexes and an inflammatory infiltrate of macrophages, B cells, and T cells in kidneys of LXR DKO but not WT mice (Figures 6E-6G ; Figure S12A ). This observation is consistent with the development of age-dependent autoimmune disease resulting from autoantibody production. Moreover, the pathological changes in LXR DKO mice were associated with compromised renal function. Alterations in diuresis and urea excretion as well as markedly increased urinary protein concentrations were observed in a majority of 40-week-old LXR DKO mice (Table S1 ). We also observed immunoglobulin deposition in multiple other tissues including lung and skin of LXR DKO mice, consistent with systemic autoimmune disease ( Figures  S12B and S12C) .
Full manifestation of the autoimmune phenotype required the combined deletion of both LXRa and LXRb, consistent with the idea that macrophages (which express both LXRs) rather than lymphocytes (which express only LXRb) are the primary cause of this pathology ( Figure S13A) . Accordingly, the dramatic lymphoid hyperplasia and marked defects in apoptotic cell uptake and repression of inflammatory gene expression were observed only in mice and cells lacking both LXRa and LXRb (data not shown). The autoimmune phenotype of LXR-deficient mice is highly reminiscent of that of Mertk À/À mice (Cohen et al., 2002) . By contrast, similar disease was not observed in background-matched mice lacking the previously described LXR target genes Apoe and Abcg1 ( Figure S13A ). We also did not observe an increase in immunoglobulin deposition in Abca1 À/À mice compared to background-matched controls ( Figure S13B ). Thus, it does not appear that loss of either Abca1 or ApoE alone can explain the autoimmune phenotype of the LXR DKO mice.
LXR Activation Ameliorates Lupus-like Autoimmune Disease in Mice
Finally, we investigated whether pharmacological activation of LXR altered the development of autoimmune disease. Macrophages derived from B6 lpr/lpr mice exhibited reduced phagocytic capacity compared to controls, consistent with prior work (Licht et al., 2004; Potter et al., 2003; Qian et al., 2006) . Remarkably, treatment of B6 lpr/lpr macrophages with LXR agonist restored both phagocytic capacity and Mer expression to above basal control levels ( Figures 7A and 7B ). To determine whether systemic administration of LXR agonist could ameliorate autoimmune disease, female B6 lpr/lpr mice were treated for 4 months with GW3965. Positron emission tomography and computed tomography (PET and CT) imaging revealed a marked decrease in lymphadenopathy in GW3965-treated animals ( Figure 7C ). Visual inspection of the lymph nodes found 90% decrease in total cellularity ( Figure 7D ). FACS analysis did not reveal any substantial differences in the frequency of specific immune cells in LN and spleen (data not shown). Although the extent of renal disease is mild on the B6 background, LXR nevertheless substantially reduced glomerular antibody deposition in B6 lpr/lpr mice ( Figure 7E ). Collectively, these results indicate that an intact LXR signaling pathway is important for Mer expression, apoptotic cell clearance, and the maintenance of immune tolerance, and that pharmacologic activation of LXR antagonizes the pathogenesis of autoimmune disease.
DISCUSSION
The balance between cell death and cell survival is crucial for tissue homeostasis in multicellular organisms (Green, 2003) . Unwanted cells are usually eliminated by apoptosis, a programmed cellular suicide conserved from worms to mammals that culminates in recognition and ingestion of dying cells by phagocytes (Henson and Hume, 2006; Ravichandran and Lorenz, 2007) . In contrast to other types of phagocytosis, such as bacterial or necrotic cell uptake, scavenging of apoptotic cells is immunologically silent (Lauber et al., 2004) . Efficient disposal of apoptotic corpses prevents uncontrolled release of intracellular contents and is important for immunological self-tolerance (Ravichandran and Lorenz, 2007) . Intracellular pathways that link the engulfment of apoptotic corpses and suppression of inflammation are incompletely characterized. We have shown here that the nuclear receptor LXR is important for both Prior work has shown LXR to be critical for macrophage cholesterol homeostasis (Castrillo and Tontonoz, 2004; Repa and Mangelsdorf, 2002) . In response to lipoprotein uptake via scavenger receptors, macrophages activate an LXR-dependent pathway for cholesterol efflux. Unexpectedly, we found that phagocytosis of apoptotic cells also activates LXR, likely through the accumulation of membrane-derived cholesterol. LXR in turn activates transcription of Mer, thereby providing positive feedback to promote further clearance, as well as genes such as Abca1 and Abcg1 to promote efflux of the excess cholesterol . At the same time, LXR activation in response to apoptotic cells also suppresses the production of inflammatory mediators. Because cholesterol is not a component of pathogens such as bacteria, activation of LXR by apoptotic cell-derived cholesterol provides a mechanism to suppress inflammatory responses in some phagocytic pathways but permit them in others.
Collectively, our data provide a new physiological context in which to view the dual activation and transrepression functions of LXR. Activation of genes such as Abca1 fits well with the established function of this receptor in cholesterol homeostasis. The biological significance of LXR's transrepressive function, however, has been less clear. Is the ability to repress inflammatory gene expression related to cholesterol metabolism, or is this an activity that evolved for a completely separate purpose? We have shown that the process of apoptotic cell clearance integrates both direct gene activation and transrepression and that, at least in this context, inhibition of inflammatory gene expression is intimately linked to metabolism of apoptotic cell lipids. These results illustrate that the activation and transrepression functions of LXR are both important for normal immune homeostasis.
Considerable data support the idea that defective clearance of apoptotic cells leads to autoimmunity (Henson and Hume, 2006; Savill et al., 2002; Vaux and Flavell, 2000) . For example, SLE patients exhibit an impaired ability to clear apoptotic cells, and corpses and DNA remnants are found in their serum (Herrmann et al., 1998; Kalden, 1997; Licht et al., 2004) . In mice lacking Mfge8, Mer, or C1q, lupus-like manifestations have been linked to inefficient removal of apoptotic cells (Botto et al., 1998; Cohen et al., 2002; Hanayama et al., 2004) . We have shown that loss of LXR-dependent regulation of Mer and inappropriate activation of inflammatory signaling during phagocytosis leads to the development of autoimmune disease. Interestingly, Mertk À/À and LXR DKO mice share a number of striking similarities, including exacerbated inflammatory responses and increased susceptibility to both autoimmunity and atherosclerosis (Ait-Oufella et al., 2008; Camenisch et al., 1999; Cohen et al., 2002; Joseph et al., 2003; Thorp et al., 2008) . At the same time, the fact that autoimmune disease is more severe in LXR DKO compared to Mer-deficient mice suggests that more than one LXR-dependent pathway may be involved. We have recently shown that loss of LXRb leads to increased lymphocyte proliferation (Bensinger et al., 2008) . It is likely that the phenotype of LXR DKO mice reflects both the action of LXRa and LXRb in antigen-presenting cells as well as the autonomous effect of LXRb in lymphocytes. It is also possible that loss of regulation of ABCA1, ApoE (Grainger et al., 2004; Hamon et al., 2000) , and other targets contributes to the autoimmune phenotype of LXR-deficient mice. The question of whether defects in the LXR signaling pathway may contribute to the development of human autoimmune disease remains to be investigated. Finally, we have shown that pharmacological LXR activation has beneficial effects on the progression of autoimmune disease in mouse models of lupus-like disease. A previous study reported that a different LXR agonist slowed the development of disease in an experimental autoimmune encephalomyelitis model, although the underlying mechanism was not addressed (Hindinger et al., 2006) . Our studies indicate that LXR activation may compensate for the macrophage phagocytic defect characteristic of lupus-like autoimmunity. In addition, it is likely that the ability of LXRs to directly suppress inflammation and inhibit lymphocyte proliferation also contribute to the therapeutic effects of LXR agonists in these disease models. Further studies will be required to explore the possibility that LXR agonists may have utility in the therapy of human autoimmune disease. 
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À/À ) mice on mixed Sv129/C57Bl/6 and C57Bl/6 (backcrossed more than ten generations) backgrounds were provided by David Mangelsdorf (UTSW) (Peet et al., 1998) . C57Bl/6 Apoe À/À mice were purchased from Jackson Laboratories. C57Bl/6 Abcg1 À/À and Sv129/C57Bl/6 Abca1 À/À mice and their WT controls have been described previously (Kennedy et al., 2005; Timmins et al., 2005) . Mice congenic for the spontaneous mutation Fas lpr (B6 lpr/lpr ) were purchased from the Jackson Laboratory. For LXR ligand treatment in vivo, WT or autoimmune-prone mice were fed a standard chow diet with or without 20 mg/kg/day GW3965. Age-matched female B6 lpr/lpr mice were maintained on diet for 4 months. For imaging studies, mice were sedated and injected with PET probe L-FMAC, and PET/CT imaging was performed as previously reported (Radu et al., 2008) . Images were analyzed with AMIDE software. All mice were maintained under pathogen-free conditions in the animal facilities of the University of California, Los Angeles (UCLA) and University of Las Palmas (ULPGC). Urine samples were collected from individual metabolic cages (kindly donated by L. Fernandez-Perez) and analyzed at the Servicio de Bioquimica Hospital Insular. All animal studies were conducted in accordance with the UCLA and ULPGC Animal Research Committees.
Reagents
The following antibodies and conjugates were used in this study: Mucosal addressin cell adhesion molecule (MAdCAM-1, eBioscience) CD68 (clone FA-11; Serotec), anti-CD4 (clone H129.19; BD PharMingen), anti-CD8a (clone 53-6.7; BD PharMingen), anti-CD45R (B220, clone RA3-6B2; Ebioscience), antimouse-Mer (R&D Systems), Alexa Fluor 647-anti-F4/80 (clone BM8; eBiosciences), rat anti-mouse F4/80 (kindly provided by S. Gordon and M. Stacey), anti-CD11b-FITC (Clone m1/70; PharMingen), anti-mouse-IgG-FITC (Sigma), Alexa Fluor 488-anti-rat-IgG and IgM (Molecular Probes), Alexa Fluor 594-anti-rat-IgG and IgM (Molecular probes), Alexa Fluor 350-anti rat-IgG, and anti-rat byotinilated immunoglobulin (Dako Cytomation). Anti-mouse CD25 (PC61), CD3 (2C11), CD4 (RM4-5), CD8 (53-6.7), CD28 (37.51), CD69 (HI.2F3), Foxp3 (FJK-16 s), CD19 (1D3), CD11c (N418), CD11b (M1/70), and F4/80 (BM8) were purchased from BD Biosciences. FITC-peanut agglutinin (PNA) was purchased from Vector Laboratories. CellTracker Green CMFDA (5-chloromethylfluorescein diacetate) and CellTracker Red CMTPX from Molecular Probes were used to stain viable cultured cells in vitro. To quantify free apoptotic cells in culture or from tissues, Annexin V-FITC Apoptosis Detection Kit from BD PharMingen was used. Apoptotic cells in tissues were also identified by TUNEL reaction according to the instructions of the manufacturer with an In situ Cell Death Detection Kit from Roche. Fluorescent Latex beads, carboxilate-modified polystyrene yellow-green (Sigma), and GFP-E. coli (a gift from G. Cheng, UCLA) were used for phagocytosis assays.
Cell Culture and Transfections
Bone marrow-derived macrophages (BMDM) and thioglycolate (TG)-elicited peritoneal macrophages were obtained as described (Castrillo et al., 2003b) . Macrophages were cultured in RPMI or DMEM containing 10% fetal bovine serum (FBS, Omega Scientific). For ligand treatments, cells were cultured in medium supplemented with 0.5% BSA and receptor ligands in DMSO vehicle. RAW-LXRa and RAW-FLAG-LXRa stable cell line were generated by retroviral transduction with a pBabe-puro-based expression vector as previously described (Chen et al., 2006; Venkateswaran et al., 2000) . RAW-Mer stable cell lines were generated by cotransfection of a pCDNA-Mer expression vector (kindly provided by D.K. Graham) along with a G418 resistance plasmid (Graham et al., 1995) . Multiple clones were selected and analyzed for Mer mRNA expression and two independent clones were chosen for analysis. Knockdown studies were performed in RAW-LXRa cells with Amaxa Nucleofection kit specific for mouse macrophages and different specific murine MER siRNAs (Dharmacon) or nonspecific siRNA according to the instructions of the manufacturer. Transfection efficiency was determined by GFP-expressing cells. An average of 50%-60% transfection efficiency was achieved with this method. Studies with MER blocking antibody were performed in WT and LXR DKO macrophages. 50 mg/ml of Mer antibody (R&D systems) was added to RPMI medium for 3 hr before phagocytosis assays (see below).
In Vitro Phagocytosis Assays
In vitro phagocytosis assays with mouse macrophages were carried out essentially as described (Hanayama et al., 2002; Scott et al., 2001; Yamauchi et al., 2004) . Primary peritoneal macrophages were recovered from mice injected with 3% thyoglicolate for 3 days. Cells were pelleted and resuspended in RPMI (Cambrex) medium suplemented with 10% FCS (Lonza) and 5 3 10 5 cells were plated on sterile glass coverslips. To generate apoptotic thymocytes (AT), thymi from 3-to 4-week-old C57BL/6 mice were harvested and mechanically disociated, filtered, pelleted, and resuspended in RPMI medium supplemented with 10% FCS. Apoptosis was induced by treatment with 1 mM of dexamethasone (Sigma) for 6 hr. This method results in 60%-80% thymocyte apoptosis, as measured with FITC-AnnexinV staining (BD). AT were washed twice with PBS and fluorescein labeled with CellTracker green (Invitrogen) according to the manufacturer's instructions. Fluorescent AT were added to peritoneal macrophages in a 5:1 ratio (ATs:macrophages) and cultured at 37 C for 30, 60, or 90 min in RPMI supplemented with 10% FBS. After incubation with ATs, macrophages were gently washed several times with cold PBS and Cell Dissociation Buffer, Enzyme Free PBS-based (Invitrogen) to remove free apoptotic thymocytes as described (Krysko et al., 2006; Yamauchi et al., 2004) . Cells were then fixed with 2% paraformaldehyde, and phagocytosis was scored with confocal fluorescent microscopy. Phagocytosis was expressed as phagocytic index (PI): number of cells ingested per total number of macrophages 3 100 (Fadok et al., 1998b; Hanayama et al., 2004) . Alternatively, thymocytes were stained with CellTracker red and macrophages were visualized with F4/80 antibody. In some studies, macrophages were treated with 1 mM synthetic LXR agonist (GW3965) in RPMI supplemented with 0.5% FCS prior to addition of apoptotic cells and phagocytosis assays were performed as described above in RPMI containing 10% FBS. Latex beads and bacterial phagocytosis were performed with 1 mm carboxilate-coated fluorescent beads (Sigma) and GFP-E. coli, respectively, and cultured with macrophages for 30 min. In some experiments, sterol content from apoptotic cells was decreased by treating apoptotic thymocytes with methyl-b-cyclodextrin (MbCD, Sigma). ATs were cultured with 5 mM of MbCD in RPMI for 1 hr and then proceed with the phagocytosis assay.
In Vivo Phagocytosis Assays
For in vivo peritoneal macrophage phagocytosis assays, 1 3 10 7 CFSElabeled apoptotic thymocytes were injected i.p. into 6-to 8-week-old wildtype and LXR DKO, ApoE
were sacrificed after 1 hr, and the peritoneum was flushed with 5 ml of PBS. A single-cell suspension of peritoneal flush was stained with anti-F4/80 and CD19 to identify macrophage and B cell populations, respectively. Cells were analyzed by flow cytometry (described below). Statistical analysis was performed by Student's t test. For in vivo thymic phagocytosis assays, 4-week-old mice were injected i.p. with 0.2 mg of dexamethasone per 25 g body weight in PBS (Sigma). After 24 hr, mice were sacrificed and thymi were extracted and mechanically dissociated. Free apoptotic cells were determined with FITC-AnnexinV staining with a Coulter Epics XL-MCL (Beckman Coulter). Additionally, cells were fixed and permeabilized and total apoptotic cells were measured via the TUNEL reaction (In Situ Cell Death Detection Kit from Roche). For transmission electron microscopy analysis, mice treated for 24 hr with dexamethasone were sacrificed and perfused with fixation solution (2% glutaraldehyde). Thymi were harvested, fixed with 2% OsO 4 , dehydrated, and embedded in epoxy resin. Ultra-thin sections were stained with uranyl acetate and lead citrate and observed under electron microscope at the ULPGC electron microscopy core facility.
Histology
Tissues were collected and fixed in 4% buffered formalin, dehydrated in successive alcohol solutions, embedded in paraffin wax, and sectioned for H&E staining. Alternatively, tissues were directly collected from the animal, embedded in OCT compound (Tissue-Tek), and snap-frozen in liquid Nitrogen and Isopentane. 4 mm frozen sections were air-dried, fixed with 4% paraformaldehyde, blocked with 6% BSA and 2% preimmune serum in PBS, and stained with fluorescence-conjugated antibodies diluted in blocking solution; nuclei were stained with DAPI (Vectashield mountain medium fluorescence with DAPI, Vector). For non-fluorophore-conjugated antibodies, biotinylated secondary antibodies were visualized by the streptavidin-biotin-peroxidase method (Vectastain ABC Kit, Vector Laboratories) and stained with the cromogen 3-3 0 -diaminobenzidine tetrahydrochloride (DAB Substrate Kit for peroxidase, Vector Laboratories). Nuclei were counterstained with hematoxilin. TUNEL reaction (In Situ Cell Death Detection kit from Roche) was used to identify apoptotic cells in frozen sections from spleen, thymus, lung, and testis: 4 mm sections were fixed with 2% paraformaldehyde, permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate, and stained with the TUNEL reaction. Then, macrophages were identified in the same sections with rat antimouse-CD68 (Serotec) and visualized with secondary antibody anti-rat-Alexa Fluor 594 (Molecular Probes). Sections and pictures were observed under a Zeiss LSM 5 PASCAL Laser Scaning Microscope (Carl Zeiss, Germany).
ELISA and Biochemical Parameters
The presence of antinuclear antibodies (via a Mesacup ANA test from MBL) and autoantibodies directed against dsDNA and of histones were examined in serial dilutions of mouse serum by ELISA as described in previously (Salvador et al., 2002) . In brief, 96-well flat-bottom plates (Nunc-immuno plate F96 MAXISORP) were precoated with 2.5 mg of poly-L-lysine (Sigma) for 1 hr at 37 C. Plates were incubated with 0.5 mg/well of dsDNA, histone type II-S from calf thymus (Sigma) overnight at 4 C. After blocking the nonspecific sites with 5% FCS for 1 hr at 37 C, mice serum samples were added for 3 hr at room temperature. Then followed 1 hr of incubation with HRP-labeled goat anti-mouse IgG Fc-specific (Jackson Immunoresearch) diluted 1:500. A substrate solution containing equal volumes of Sigma Fast OPD peroxidase substrate was added. After incubation of 5 min at room temperature, reaction was stopped with 50 ml of 3M H 2 SO 4 solution and the plates were read at 492 nm in ELISA reader (Bio-Rad).
DNA, RNA, and Protein Analysis Total RNA was harvested with TRIzol reagent (Invitrogen). Total RNA was reverse-transcribed with random hexamers by using iScript reverse-transcription reagents kit (Bio-Rad) according to manufacturer protocol. Real-time quantitative PCR (SYBRgreen) assays were performed with an Applied Biosystems 7900 sequencer detector as described previously (Joseph et al., 2003; Laffitte et al., 2001) . Expression was normalized to 36B4 expression. Primer and probe sequences are available upon request. Statistical analysis of mRNA expression data was performed via the Student's t test. Probe and primer sequences are available on request. Electrophoretic mobility shift assay was performed as described previously (Laffitte et al., 2001 ). In brief, murine LXRa and RXRa proteins were synthesized with the TnT T7 quick-coupled transcription/translation system (Promega). Reaction mixture containing proteins and buffer was briefly preincubated with RXRa polyclonal antibody (Santa Cruz Biotechnology) before addition of radiolabeled oligonucleotides as indicated. The binding reactions were resolved on a pre-electrophoresed 1X TBE, 5% polyacrylamide gel. Oligonucleotides used were as follows (only one strand shown): Mer LXRE primer: 5 0 -ttcatgtgtatgctggggtaccca-3 0 , Mer
Mutant LXRE: 5 0 -ttcattttaatgcagtttaaccca-3 0 , and SREBP1c LXRE: 5 0 -cgctgg ggttactggcggtcactgta-3 0 . For northern blots, 10 mg of total RNA isolated from cells was separated by gel electrophoresis, transferred to nylon membranes, and hybridized with [a-32 P]dCTP-labeled DNA probes as described (Castrillo et al., 2003b) . Chromatin immunoprecipitation (ChIP) assays were performed essentially as described (Hecht and Grunstein, 1999) . In brief, RAW-LXRa or RAW-FLAG-LXRa macrophages were cultured with GW3965 for 1 hr and fixed with 1% formaldehyde. After cross-linking, cells were sonicated in order to obtain DNA fragments of 300-1000 bp. Immunoprecipitation was performed with the following antibodies: anti-NCoR (Affinity Bioreagents, Golden, CO), rabbit anti-RNA PolII, anti-RXRa, anti-FLAG, and anti-Rabbit IgG (Santa Cruz Biotechnology). Protein-DNA complexes were reverse cross-linked at 65 C overnight and DNA was purified with a PCR purification kit (G&E Healthcare). Fractions of DNA were used for real-time quantitative PCR. For western blot analysis, whole cell lysates were boiled and separated on a SDS-PAGE gel. Proteins were transferred onto polyvinylidene difluoride membrane (Amersham), blocked in TBS with 0.1% Tween20 and 5% milk, and incubated with the following antibodies: rabbit anti-Mer and ABCG1 from Novus Biologicals, rabbit ABCA1 antisera kindly provided by M.L. Fitzgerald (Fitzgerald et al., 2001 ) (MGH, Boston, MA), rabbit anti-ApoE from AbCAM, and secondary goat anti-rabbit HRP from Amersham. Blots were washed in TBS-T and visualized with ECL-Plus (Amersham Biosciences) and Bio-Rad Chemi-Doc imaging system.
DNA Microarray Analysis
Total RNA was isolated from RAW264.7 macrophages ectopically expressing LXRa (Venkateswaran et al., 2000) cultured with vehicle or GW3965 (1 mM) and LG268 (100 nM). Transcriptional profiling was performed at the UCLA microarray core facility with murine Affymetrix 430 2.0 microarrays. Data were analyzed with GeneSpring and GeneChip Analysis Suite software (Affymetrix) as described previously (Zelcer et al., 2007) . Only statistically significant expression differences are presented.
Flow Cytometry
Single-cell suspensions from lymph nodes and spleens were obtained from mice and washed twice in staining buffer, resuspended, and incubated with labeled antibodies diluted in staining buffer for 30 min at 4 C. After incubation, cells were washed in staining buffer and analyzed immediately. Intracellular FoxP3 staining was performed as per manufacturer's instruction (eBiosciences). Cells were analyzed on FACSCalibur or LSRII (Becton Dickinson) with FlowJo software (Treestar, Inc.). For in vivo thymic phagocytosis assay and for in vitro apoptosis analysis of thymocytes, TUNEL reaction and FITC-AnnexinV staining were analyzed on Coulter Epics XL-MCL (Beckman Coulter).
Statistical Analysis
Data were expressed as mean ± SD. Statistical analysis was performed with Student's t test for two samples. For multiple comparisons, data were evaluated by one-way analysis of variance (ANOVA). Values of p < 0.05 were considered to be significant.
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